Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 31, Issue 39
  5. Article
Volume 31, Issue 39
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Different studies have highlighted the role of Substance P / Neurokinin 1 Receptor (SP/NK-1R) axis in multiple hallmarks of cancer including cell transformation, proliferation, and migration as well as angiogenesis and metastasis of a wide range of solid tumors including colorectal cancer. Until now, the selective high-affinity antagonist of human SP/NK1-R aprepitant (Emend) has been authorized by the Food and Drug Administration as a low dosage medication to manage and treat chemotherapy-induced nausea. However, increasing evidence in recent years support the potential utility of high doses of aprepitant as an antitumor agent and thus, opening the possibility to the pharmacological repositioning of SP/NK1-R antagonists as an adjuvant therapy to conventional cancer treatments. In this review, we summarize current knowledge on the molecular basis of colorectal cancer as well as the pathophysiological importance of SP/NK1-R and the potential utility of SP/NK-1R axis as a therapeutic target in this malignancy.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673261625230924114406
2023-10-10
2025-01-15

  • From This Site

    /content/journals/cmc/10.2174/0109298673261625230924114406
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  2. SiegelR.L. MillerK.D. Goding SauerA. FedewaS.A. ButterlyL.F. AndersonJ.C. CercekA. SmithR.A. JemalA. Colorectal cancer statistics, 2020.CA Cancer J. Clin.202070314516410.3322/caac.2160132133645
     [Google Scholar]
  3. SiegelR.L. MillerK.D. WagleN.S. JemalA. Cancer statistics, 2023.CA Cancer J. Clin.2023731174810.3322/caac.2176336633525
     [Google Scholar]
  4. SiegelR.L. MillerK.D. FuchsH.E. JemalA. Cancer statistics, 2022.CA Cancer J. Clin.202272173310.3322/caac.2170835020204
     [Google Scholar]
  5. MillerK.D. NogueiraL. DevasiaT. MariottoA.B. YabroffK.R. JemalA. KramerJ. SiegelR.L. Cancer treatment and survivorship statistics, 2022.CA Cancer J. Clin.202272540943610.3322/caac.2173135736631
     [Google Scholar]
  6. OncologyA.S.C. Colorectal Cancer.Statistics2022
     [Google Scholar]
  7. OncologyE.S.f.M. FDA approves first non-invasive dna screening test for colorectal cancer.2014Available from: https://www.esmo.org/oncology-news/archive/fda-approves-first-non-invasive-dna-screening-test-for-colorectal-cancer#:~:text=The%20USA%20Food%20and%20Drug,colorectal%20cancer%20or%20its%20precursors.
  8. García-OsogobioS.M. Early detection of colorectal cancer.Endoscopy2013258891
     [Google Scholar]
  9. Diaz TasendeJ. Marín GabrielJ. Screening for colorectal cancer by fecal occult blood test.Rev. Esp. Enferm. Dig.200810031531918752358
     [Google Scholar]
  10. WangJ. LiS. LiuY. ZhangC. LiH. LaiB. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis.Cancer Med.20209136137310.1002/cam4.267331693304
     [Google Scholar]
  11. MiletteS. SicklickJ.K. LowyA.M. BrodtP. Molecular pathways: Targeting the microenvironment of liver metastases.Clin. Cancer Res.201723216390639910.1158/1078‑0432.CCR‑15‑163628615370
     [Google Scholar]
  12. JinK. GaoW. LuY. LanH. TengL. CaoF. Mechanisms regulating colorectal cancer cell metastasis into liver (Review).Oncol. Lett.201231111510.3892/ol.2011.43222740847
     [Google Scholar]
  13. SchirripaM. LenzH.J. Biomarker in colorectal cancer.Cancer J.201622315616410.1097/PPO.000000000000019027341592
     [Google Scholar]
  14. DekkerE. TanisP.J. VleugelsJ.L.A. KasiP.M. WallaceM.B. Colorectal cancer.Lancet2019394102071467148010.1016/S0140‑6736(19)32319‑031631858
     [Google Scholar]
  15. TestaU. PelosiE. CastelliG. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.Med. Sci. (Basel)2018623110.3390/medsci602003129652830
     [Google Scholar]
  16. SiegelR.L. FedewaS.A. AndersonW.F. MillerK.D. MaJ. RosenbergP.S. JemalA. Colorectal cancer incidence patterns in the united states, 1974–2013.J. Natl. Cancer Inst.20171098djw32210.1093/jnci/djw32228376186
     [Google Scholar]
  17. WhiffinN. HoskingF.J. FarringtonS.M. PallesC. DobbinsS.E. ZgagaL. LloydA. KinnersleyB. GormanM. TenesaA. BroderickP. WangY. BarclayE. HaywardC. MartinL. BuchananD.D. WinA.K. HopperJ. JenkinsM. LindorN.M. NewcombP.A. GallingerS. ContiD. SchumacherF. CaseyG. LiuT. CampbellH. LindblomA. HoulstonR.S. TomlinsonI.P. DunlopM.G. Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis.Hum. Mol. Genet.201423174729473710.1093/hmg/ddu17724737748
     [Google Scholar]
  18. HawkE.T. LimburgP.J. VinerJ.L. Epidemiology and prevention of colorectal cancer.Surg. Clin. North Am.200282590594110.1016/S0039‑6109(02)00046‑412507200
     [Google Scholar]
  19. FearonE.R. Molecular genetics of colorectal cancer.Annu. Rev. Pathol.20116147950710.1146/annurev‑pathol‑011110‑13023521090969
     [Google Scholar]
  20. BowerJ.J. VanceL.D. PsiodaM. Smith-RoeS.L. SimpsonD.A. IbrahimJ.G. HoadleyK.A. PerouC.M. KaufmannW.K. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.NPJ Breast Cancer201731910.1038/s41523‑017‑0009‑728649649
     [Google Scholar]
  21. TaylorD.P. BurtR.W. WilliamsM.S. HaugP.J. Cannon-AlbrightL.A. Population-based family history-specific risks for colorectal cancer: A constellation approach.Gastroenterology2010138387788510.1053/j.gastro.2009.11.04419932107
     [Google Scholar]
  22. RustgiA.K. The genetics of hereditary colon cancer.Genes Dev.200721202525253810.1101/gad.159310717938238
     [Google Scholar]
  23. EadenJ.A. AbramsK.R. MayberryJ.F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis.Gut200148452653510.1136/gut.48.4.52611247898
     [Google Scholar]
  24. GillespieE. LeemanS.E. WattsL.A. CoukosJ.A. O’BrienM.J. CerdaS.R. FarrayeF.A. StucchiA.F. BeckerJ.M. Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.Proc. Natl. Acad. Sci.201110842174201742510.1073/pnas.111427510821969570
     [Google Scholar]
  25. FarrayeF.A. OdzeR.D. EadenJ. ItzkowitzS.H. McCabeR.P. DassopoulosT. LewisJ.D. UllmanT.A. JamesT.III McLeodR. BurgartL.J. AllenJ. BrillJ.V. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease.Gastroenterology2010138273874510.1053/j.gastro.2009.12.03720141808
     [Google Scholar]
  26. MunkholmP. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease.Aliment. Pharmacol. Ther.200318Suppl. 21510.1046/j.1365‑2036.18.s2.2.x12950413
     [Google Scholar]
  27. KimE.R. ChangD.K. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis.World J. Gastroenterol.201420299872988110.3748/wjg.v20.i29.987225110418
     [Google Scholar]
  28. IsidroR.A. CruzM.L. IsidroA.A. BaezA. ArroyoA. González-MarquésW.A. González-KeelanC. TorresE.A. AppleyardC.B. Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.World J. Gastroenterol.20152161749175810.3748/wjg.v21.i6.174925684939
     [Google Scholar]
  29. NojadehJ.N. Behrouz SharifS. SakhiniaE. Microsatellite instability in colorectal cancer.EXCLI J.20181715916810.17179/excli2017‑94829743854
     [Google Scholar]
  30. JiricnyJ. The multifaceted mismatch-repair system.Nat. Rev. Mol. Cell Biol.20067533534610.1038/nrm190716612326
     [Google Scholar]
  31. MalkiA. ElRuzR.A. GuptaI. AllouchA. VranicS. Al MoustafaA.E. Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements.Int. J. Mol. Sci.202022113010.3390/ijms2201013033374459
     [Google Scholar]
  32. PoynterJ.N. SiegmundK.D. WeisenbergerD.J. LongT.I. ThibodeauS.N. LindorN. YoungJ. JenkinsM.A. HopperJ.L. BaronJ.A. BuchananD. CaseyG. LevineA.J. MarchandL.L. GallingerS. BapatB. PotterJ.D. NewcombP.A. HaileR.W. LairdP.W. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.Cancer Epidemiol. Biomarkers Prev.200817113208321510.1158/1055‑9965.EPI‑08‑051218990764
     [Google Scholar]
  33. BattaglinF. NaseemM. LenzH.J. SalemM.E. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.Clin. Adv. Hematol. Oncol.2018161173574530543589
     [Google Scholar]
  34. SahinI.H. CiomborK.K. DiazL.A. YuJ. KimR. Immunotherapy for microsatellite stable colorectal cancers: Challenges and novel therapeutic avenues.Am. Soc. Clin. Oncol. Educ. Book2022424224225310.1200/EDBK_34981135658496
     [Google Scholar]
  35. PoulogiannisG. IchimuraK. HamoudiR.A. LuoF. LeungS.Y. YuenS.T. HarrisonD.J. WyllieA.H. ArendsM.J. Prognostic relevance of DNA copy number changes in colorectal cancer.J. Pathol.2010220333834710.1002/path.264019911421
     [Google Scholar]
  36. SilvaA.L. DawsonS.N. ArendsM.J. GuttulaK. HallN. CameronE.A. HuangT.H.M. BrentonJ.D. TavaréS. BienzM. IbrahimA.E.K. Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists.BMC Cancer201414189110.1186/1471‑2407‑14‑89125432628
     [Google Scholar]
  37. FoddeR. The APC gene in colorectal cancer.Eur. J. Cancer200238786787110.1016/S0959‑8049(02)00040‑011978510
     [Google Scholar]
  38. FearonE.R. VogelsteinB. A genetic model for colorectal tumorigenesis.Cell199061575976710.1016/0092‑8674(90)90186‑I2188735
     [Google Scholar]
  39. BienzM. CleversH. Linking colorectal cancer to Wnt signaling.Cell2000103231132010.1016/S0092‑8674(00)00122‑711057903
     [Google Scholar]
  40. MüllerM.F. IbrahimA.E.K. ArendsM.J. Molecular pathological classification of colorectal cancer.Virchows Arch.2016469212513410.1007/s00428‑016‑1956‑327325016
     [Google Scholar]
  41. LiaoW. OvermanM.J. BoutinA.T. ShangX. ZhaoD. DeyP. LiJ. WangG. LanZ. LiJ. TangM. JiangS. MaX. ChenP. KatkhudaR. KorphaisarnK. ChakravartiD. ChangA. SpringD.J. ChangQ. ZhangJ. MaruD.M. MaedaD.Y. ZebalaJ.A. KopetzS. WangY.A. DePinhoR.A. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer.Cancer Cell2019354559572.e710.1016/j.ccell.2019.02.00830905761
     [Google Scholar]
  42. de SánchezM.T.G. Cáncer colorrectal (CCR).Rev. Colomb. Gastroenterol.2005204353
     [Google Scholar]
  43. GerstungM. JollyC. LeshchinerI. DentroS.C. GonzalezS. RosebrockD. MitchellT.J. RubanovaY. AnurP. YuK. TarabichiM. DeshwarA. WintersingerJ. KleinheinzK. Vázquez-GarcíaI. HaaseK. JermanL. SenguptaS. MacintyreG. MalikicS. DonmezN. LivitzD.G. CmeroM. DemeulemeesterJ. SchumacherS. FanY. YaoX. LeeJ. SchlesnerM. BoutrosP.C. BowtellD.D. ZhuH. GetzG. ImielinskiM. BeroukhimR. SahinalpS.C. JiY. PeiferM. MarkowetzF. MustonenV. YuanK. WangW. MorrisQ.D. DentroS.C. LeshchinerI. GerstungM. JollyC. HaaseK. TarabichiM. WintersingerJ. DeshwarA.G. YuK. GonzalezS. RubanovaY. MacintyreG. AdamsD.J. AnurP. BeroukhimR. BoutrosP.C. BowtellD.D. CampbellP.J. CaoS. ChristieE.L. CmeroM. CunY. DawsonK.J. DemeulemeesterJ. DonmezN. DrewsR.M. EilsR. FanY. FittallM. GarsedD.W. GetzG. HaG. ImielinskiM. JermanL. JiY. KleinheinzK. LeeJ. Lee-SixH. LivitzD.G. MalikicS. MarkowetzF. MartincorenaI. MitchellT.J. MustonenV. OesperL. PeiferM. PetoM. RaphaelB.J. RosebrockD. SahinalpS.C. SalcedoA. SchlesnerM. SchumacherS. SenguptaS. ShiR. ShinS.J. SpiroO. SteinL.D. Vázquez-GarcíaI. VembuS. WheelerD.A. YangT-P. YaoX. YuanK. ZhuH. WangW. MorrisQ.D. SpellmanP.T. WedgeD.C. Van LooP. SpellmanP.T. WedgeD.C. Van LooP. AaltonenL.A. AbascalF. AbeshouseA. AburataniH. AdamsD.J. AgrawalN. AhnK.S. AhnS-M. AikataH. AkbaniR. AkdemirK.C. Al-AhmadieH. Al-SedairyS.T. Al-ShahrourF. AlawiM. AlbertM. AldapeK. AlexandrovL.B. AllyA. AlsopK. AlvarezE.G. AmaryF. AminS.B. AminouB. AmmerpohlO. AndersonM.J. AngY. AntonelloD. AnurP. AparicioS. AppelbaumE.L. AraiY. AretzA. ArihiroK. AriizumiS. ArmeniaJ. ArnouldL. AsaS. AssenovY. AtwalG. AukemaS. AumanJ.T. AureM.R.R. AwadallaP. AymerichM. BaderG.D. Baez-OrtegaA. BaileyM.H. BaileyP.J. BalasundaramM. BaluS. BandopadhayayP. BanksR.E. BarbiS. BarbourA.P. BarenboimJ. Barnholtz-SloanJ. BarrH. BarreraE. BartlettJ. BartolomeJ. BassiC. BatheO.F. BaumhoerD. BaviP. BaylinS.B. BazantW. BeardsmoreD. BeckT.A. BehjatiS. BehrenA. NiuB. BellC. BeltranS. BenzC. BerchuckA. BergmannA.K. BergstromE.N. BermanB.P. BerneyD.M. BernhartS.H. BeroukhimR. BerriosM. BersaniS. BertlJ. BetancourtM. BhandariV. BhosleS.G. BiankinA.V. BiegM. BignerD. BinderH. BirneyE. BirrerM. BiswasN.K. BjerkehagenB. BodenheimerT. BoiceL. BonizzatoG. De BonoJ.S. BootA. BootwallaM.S. BorgA. BorkhardtA. BoroevichK.A. BorozanI. BorstC. BosenbergM. BosioM. BoultwoodJ. BourqueG. BoutrosP.C. BovaG.S. BowenD.T. BowlbyR. BowtellD.D.L. BoyaultS. BoyceR. BoydJ. BrazmaA. BrennanP. BrewerD.S. BrinkmanA.B. BristowR.G. BroaddusR.R. BrockJ.E. BrockM. BroeksA. BrooksA.N. BrooksD. BrorsB. BrunakS. BruxnerT.J.C. BruzosA.L. BuchananA. BuchhalterI. BuchholzC. BullmanS. BurkeH. BurkhardtB. BurnsK.H. BusanovichJ. BustamanteC.D. ButlerA.P. ButteA.J. ByrneN.J. Børresen-DaleA-L. Caesar-JohnsonS.J. CafferkeyA. CahillD. CalabreseC. CaldasC. CalvoF. CamachoN. CampbellP.J. CampoE. CantùC. CaoS. CareyT.E. Carlevaro-FitaJ. CarlsenR. CataldoI. CazzolaM. CebonJ. CerfolioR. ChadwickD.E. ChakravartyD. ChalmersD. ChanC.W.Y. ChanK. Chan-Seng-YueM. ChandanV.S. ChangD.K. ChanockS.J. ChantrillL.A. ChateignerA. ChatterjeeN. ChayamaK. ChenH-W. ChenJ. ChenK. ChenY. ChenZ. CherniackA.D. ChienJ. ChiewY-E. ChinS-F. ChoJ. ChoS. ChoiJ.K. ChoiW. ChomienneC. ChongZ. ChooS.P. ChouA. ChristA.N. ChristieE.L. ChuahE. CibulskisC. CibulskisK. CingarliniS. ClaphamP. ClaviezA. ClearyS. CloonanN. CmeroM. CollinsC.C. ConnorA.A. CookeS.L. CooperC.S. CopeL. CorboV. CordesM.G. CordnerS.M. Cortés-CirianoI. CovingtonK. CowinP.A. CraftB. CraftD. CreightonC.J. CunY. CurleyE. CutcutacheI. CzajkaK. CzerniakB. DaggR.A. DanilovaL. DaviM.V. DavidsonN.R. DaviesH. DavisI.J. Davis-DusenberyB.N. DawsonK.J. De La VegaF.M. De Paoli-IseppiR. DefreitasT. TosA.P.D. DelaneauO. DemchokJ.A. DemeulemeesterJ. DemidovG.M. DemircioğluD. DennisN.M. DenrocheR.E. DentroS.C. DesaiN. DeshpandeV. DeshwarA.G. DesmedtC. Deu-PonsJ. DhallaN. DhaniN.C. DhingraP. DhirR. DiBiaseA. DiamantiK. DingL. DingS. DinhH.Q. DirixL. DoddapaneniH.V. DonmezN. DowM.T. DrapkinR. DrechselO. DrewsR.M. SergeS. DudderidgeT. Dueso-BarrosoA. DunfordA.J. DunnM. DursiL.J. DuthieF.R. Dutton-RegesterK. EaglesJ. EastonD.F. EdmondsS. EdwardsP.A. EdwardsS.E. EelesR.A. EhingerA. EilsJ. EilsR. El-NaggarA. EldridgeM. EllrottK. ErkekS. EscaramisG. EspirituS.M.G. EstivillX. EtemadmoghadamD. EyfjordJ.E. FaltasB.M. FanD. FanY. FaquinW.C. FarcasC. FassanM. FatimaA. FaveroF. FayzullaevN. FelauI. FeredayS. FergusonM.L. FerrettiV. FeuerbachL. FieldM.A. FinkJ.L. FinocchiaroG. FisherC. FittallM.W. FitzgeraldA. FitzgeraldR.C. FlanaganA.M. FleshnerN.E. FlicekP. FoekensJ.A. FongK.M. FonsecaN.A. FosterC.S. FoxN.S. FraserM. FrazerS. Frenkel-MorgensternM. FriedmanW. FrigolaJ. FronickC.C. FujimotoA. FujitaM. FukayamaM. FultonL.A. FultonR.S. FurutaM. FutrealP.A. FüllgrabeA. GabrielS.B. GallingerS. Gambacorti-PasseriniC. GaoJ. GaoS. GarrawayL. GarredØ. GarrisonE. GarsedD.W. GehlenborgN. GelpiJ.L.L. GeorgeJ. GerhardD.S. GerhauserC. GershenwaldJ.E. GersteinM. GerstungM. GetzG. GhoriM. GhosseinR. GiamaN.H. GibbsR.A. GibsonB. GillA.J. GillP. GiriD.D. GlodzikD. GnanapragasamV.J. GoeblerM.E. GoldmanM.J. GomezC. GonzalezS. Gonzalez-PerezA. GordeninD.A. GossageJ. GotohK. GovindanR. GrabauD. GrahamJ.S. GrantR.C. GreenA.R. GreenE. GregerL. GrehanN. GrimaldiS. GrimmondS.M. GrossmanR.L. GrundhoffA. GundemG. GuoQ. GuptaM. GuptaS. GutI.G. GutM. GökeJ. HaG. HaakeA. HaanD. HaasS. HaaseK. HaberJ.E. HabermannN. HachF. HaiderS. HamaN. HamdyF.C. HamiltonA. HamiltonM.P. HanL. HannaG.B. HansmannM. HaradhvalaN.J. HarismendyO. HarliwongI. HarmanciA.O. HarringtonE. HasegawaT. HausslerD. HawkinsS. HayamiS. HayashiS. HayesD.N. HayesS.J. HaywardN.K. HazellS. HeY. HeathA.P. HeathS.C. HedleyD. HegdeA.M. HeimanD.I. HeinoldM.C. HeinsZ. HeislerL.E. Hellstrom-LindbergE. HelmyM. HeoS.G. HepperlaA.J. Heredia-GenestarJ.M. HerrmannC. HerseyP. HessJ.M. HilmarsdottirH. HintonJ. HiranoS. HiraokaN. HoadleyK.A. HobolthA. HodzicE. HoellJ.I. HoffmannS. HofmannO. HolbrookA. HolikA.Z. HollingsworthM.A. HolmesO. HoltR.A. HongC. HongE.P. HongJ.H. HooijerG.K. HornshøjH. HosodaF. HouY. HovestadtV. HowatW. HoyleA.P. HrubanR.H. HuJ. HuT. HuaX. HuangK. HuangM. HuangM.N. HuangV. HuangY. HuberW. HudsonT.J. HummelM. HungJ.A. HuntsmanD. HuppT.R. HuseJ. HuskaM.R. HutterB. HutterC.M. HübschmannD. Iacobuzio-DonahueC.A. ImbuschC.D. ImielinskiM. ImotoS. IsaacsW.B. IsaevK. IshikawaS. IskarM. IslamS.M.A. IttmannM. IvkovicS. IzarzugazaJ.M.G. JacquemierJ. JakrotV. JamiesonN.B. JangG.H. JangS.J. JayaseelanJ.C. JayasingheR. JefferysS.R. JegalianK. JenningsJ.L. JeonS-H. JermanL. JiY. JiaoW. JohanssonP.A. JohnsA.L. JohnsJ. JohnsonR. JohnsonT.A. JollyC. JolyY. JonassonJ.G. JonesC.D. JonesD.R. JonesD.T.W. JonesN. JonesS.J.M. JonkersJ. JuY.S. JuhlH. JungJ. JuulM. JuulR.I. JuulS. JägerN. KabbeR. KahlesA. KahramanA. KaiserV.B. KakavandH. KalimuthuS. von KalleC. KangK.J. KarasziK. KarlanB. KarlićR. KarschD. KasaianK. KassahnK.S. KataiH. KatoM. KatohH. KawakamiY. KayJ.D. KazakoffS.H. KazanovM.D. KeaysM. KebebewE. KeffordR.F. KellisM. KenchJ.G. KennedyC.J. KerssemakersJ.N.A. KhooD. KhooV. KhuntikeoN. KhuranaE. KilpinenH. KimH.K. KimH-L. KimH-Y. KimH. KimJ. KimJ. KimJ.K. KimY. KingT.A. KlapperW. KleinheinzK. KlimczakL.J. KnappskogS. KnebaM. KnoppersB.M. KohY. KomorowskiJ. KomuraD. KomuraM. KongG. KoolM. KorbelJ.O. KorchinaV. KorshunovA. KoscherM. KosterR. Kote-JaraiZ. KouresA. KovacevicM. KremeyerB. KretzmerH. KreuzM. KrishnamurthyS. KubeD. KumarK. KumarP. KumarS. KumarY. KundraR. KüblerK. KüppersR. LagergrenJ. LaiP.H. LairdP.W. LakhaniS.R. LalansinghC.M. LalondeE. LamazeF.C. LambertA. LanderE. LandgrafP. LandoniL. LangerødA. LanzósA. LarsimontD. LarssonE. LathropM. LauL.M.S. LawerenzC. LawlorR.T. LawrenceM.S. LazarA.J. LazicA.M. LeX. LeeD. LeeD. LeeE.A. LeeH.J. LeeJ.J-K. LeeJ-Y. LeeJ. LeeM.T.M. Lee-SixH. LehmannK-V. LehrachH. LenzeD. LeonardC.R. LeongamornlertD.A. LeshchinerI. LetourneauL. LetunicI. LevineD.A. LewisL. LeyT. LiC. LiC.H. LiH.I. LiJ. LiL. LiS. LiS. LiX. LiX. LiX. LiY. LiangH. LiangS-B. LichterP. LinP. LinZ. LinehanW.M. LingjærdeO.C. LiuD. LiuE.M. LiuF-F.F. LiuF. LiuJ. LiuX. LivingstoneJ. LivitzD. LivniN. LochovskyL. LoefflerM. LongG.V. Lopez-GuillermoA. LouS. LouisD.N. LovatL.B. LuY. LuY-J. LuY. LuchiniC. LunguI. LuoX. LuxtonH.J. LynchA.G. LypeL. LópezC. López-OtínC. MaE.Z. MaY. MacGroganG. MacRaeS. MacintyreG. MadsenT. MaejimaK. MafficiniA. MaglinteD.T. MaitraA. MajumderP.P. MalcovatiL. MalikicS. MalleoG. MannG.J. Mantovani-LöfflerL. MarchalK. MarchegianiG. MardisE.R. MargolinA.A. MarinM.G. MarkowetzF. MarkowskiJ. MarksJ. Marques-BonetT. MarraM.A. MarsdenL. MartensJ.W.M. MartinS. Martin-SuberoJ.I. MartincorenaI. Martinez- FundichelyA. MaruvkaY.E. MashlR.J. MassieC.E. MatthewT.J. MatthewsL. MayerE. MayesS. MayoM. MbabaaliF. McCuneK. McDermottU. McGillivrayP.D. McLellanM.D. McPhersonJ.D. McPhersonJ.R. McPhersonT.A. MeierS.R. MengA. MengS. MenziesA. MerrettN.D. MersonS. MeyersonM. MeyersonW. MieczkowskiP.A. MihaiescuG.L. MijalkovicS. MikkelsenT. MilellaM. MileshkinL. MillerC.A. MillerD.K. MillerJ.K. MillsG.B. MilovanovicA. MinnerS. MiottoM. ArnauG.M. MirabelloL. MitchellC. MitchellT.J. MiyanoS. MiyoshiN. MizunoS. Molnár-GáborF. MooreM.J. MooreR.A. MorganellaS. MorrisQ.D. MorrisonC. MoseL.E. MoserC.D. MuiñosF. MularoniL. MungallA.J. MungallK. MusgroveE.A. MustonenV. MutchD. MuyasF. MuznyD.M. MuñozA. MyersJ. MyklebostO. MöllerP. NagaeG. NagrialA.M. Nahal- BoseH.K. NakagamaH. NakagawaH. NakamuraH. NakamuraT. NakanoK. NandiT. NangaliaJ. NasticM. NavarroA. NavarroF.C.P. NealD.E. NettekovenG. NewellF. NewhouseS.J. NewtonY. NgA.W.T. NgA. NicholsonJ. NicolD. NieY. NielsenG.P. NielsenM.M. Nik-ZainalS. NobleM.S. NonesK. NorthcottP.A. NottaF. O’ConnorB.D. O’DonnellP. O’DonovanM. O’MearaS. O’NeillB.P. O’NeillJ.R. OcanaD. OchoaA. OesperL. OgdenC. OhdanH. OhiK. Ohno-MachadoL. OienK.A. OjesinaA.I. OjimaH. OkusakaT. OmbergL. OngC.K. OssowskiS. OttG. OuelletteB.F.F. P’ngC. PaczkowskaM. PaiellaS. PairojkulC. PajicM. Pan-HammarströmQ. PapaemmanuilE. PapatheodorouI. ParamasivamN. ParkJ.W. ParkJ-W. ParkK. ParkK. ParkP.J. ParkerJ.S. ParsonsS.L. PassH. PasternackD. PastoreA. PatchA-M. PauportéI. PeaA. PearsonJ.V. PedamalluC.S. PedersenJ.S. PederzoliP. PeiferM. PennellN.A. PerouC.M. PerryM.D. PetersenG.M. PetoM. PetrelliN. PetryszakR. PfisterS.M. PhillipsM. PichO. PickettH.A. PihlT.D. PillayN. PinderS. PineseM. PinhoA.V. PitkänenE. PivotX. Piñeiro-YáñezE. PlankoL. PlassC. PolakP. PonsT. PopescuI. PotapovaO. PrasadA. PrestonS.R. PrinzM. PritchardA.L. ProkopecS.D. ProvenzanoE. PuenteX.S. PuigS. PuiggròsM. Pulido-TamayoS. PupoG.M. PurdieC.A. QuinnM.C. RabionetR. RaderJ.S. RadlwimmerB. RadovicP. RaederB. RaineK.M. RamakrishnaM. RamakrishnanK. RamalingamS. RaphaelB.J. RathmellW.K. RauschT. ReifenbergerG. ReimandJ. Reis-FilhoJ. ReuterV. Reyes-SalazarI. ReynaM.A. ReynoldsS.M. RheinbayE. RiazalhosseiniY. RichardsonA.L. RichterJ. RingelM. RingnérM. RinoY. RippeK. RoachJ. RobertsL.R. RobertsN.D. RobertsS.A. RobertsonA.G. RobertsonA.J. RodriguezJ.B. Rodriguez-MartinB. Rodríguez-GonzálezF.G. RoehrlM.H.A. RohdeM. RokutanH. RomieuG. RoomanI. RoquesT. RosebrockD. RosenbergM. RosenstielP.C. RosenwaldA. RoweE.W. RoyoR. RozenS.G. RubanovaY. RubinM.A. Rubio-PerezC. RudnevaV.A. RusevB.C. RuzzenenteA. RätschG. SabarinathanR. SabelnykovaV.Y. SadeghiS. SahinalpS.C. SainiN. Saito-AdachiM. SaksenaG. SalcedoA. SalgadoR. SalichosL. SallariR. SallerC. SalviaR. SamM. SamraJ.S. Sanchez-VegaF. SanderC. SandersG. SarinR. SarrafiI. Sasaki-OkuA. SauerT. SauterG. SawR.P.M. ScardoniM. ScarlettC.J. ScarpaA. SceloG. SchadendorfD. ScheinJ.E. SchilhabelM.B. SchlesnerM. SchlommT. SchmidtH.K. SchrammS-J. SchreiberS. SchultzN. SchumacherS.E. SchwarzR.F. ScolyerR.A. ScottD. ScullyR. SeethalaR. SegreA.V. SelanderI. SempleC.A. SenbabaogluY. SenguptaS. SereniE. SerraS. SgroiD.C. ShackletonM. ShahN.C. ShahabiS. ShangC.A. ShangP. ShapiraO. SheltonT. ShenC. ShenH. ShepherdR. ShiR. ShiY. ShiahY-J. ShibataT. ShihJ. ShimizuE. ShimizuK. ShinS.J. ShiraishiY. ShmayaT. ShmulevichI. ShorserS.I. ShortC. ShresthaR. ShringarpureS.S. ShriverC. ShuaiS. SidiropoulosN. SiebertR. SieuwertsA.M. SieverlingL. SignorettiS. SikoraK.O. SimboloM. SimonR. SimonsJ.V. SimpsonJ.T. SimpsonP.T. SingerS. Sinnott-ArmstrongN. SipahimalaniP. SkellyT.J. SmidM. SmithJ. Smith-McCuneK. SocciN.D. SofiaH.J. SolowayM.G. SongL. SoodA.K. SothiS. SotiriouC. SouletteC.M. SpanP.N. SpellmanP.T. SperandioN. SpillaneA.J. SpiroO. SpringJ. StaafJ. StadlerP.F. StaibP. StarkS.G. StebbingsL. StefánssonÓ.A. StegleO. SteinL.D. StenhouseA. StewartC. StilgenbauerS. StobbeM.D. StrattonM.R. StretchJ.R. StruckA.J. StuartJ.M. StunnenbergH.G. SuH. SuX. SunR.X. SungaleeS. SusakH. SuzukiA. SweepF. SzczepanowskiM. SültmannH. YugawaT. TamA. TamboreroD. TanB.K.T. TanD. TanP. TanakaH. TaniguchiH. TanskanenT.J. TarabichiM. TarnuzzerR. TarpeyP. TaschukM.L. TatsunoK. TavaréS. TaylorD.F. Taylor-WeinerA. TeagueJ.W. TehB.T. TembeV. TemesJ. ThaiK. ThayerS.P. ThiessenN. ThomasG. ThomasS. ThompsonA. ThompsonA.M. ThompsonJ.F.F. ThompsonR.H. ThorneH. ThorneL.B. ThorogoodA. TiaoG. TijanicN. TimmsL.E. TiraboscoR. TojoM. TommasiS. ToonC.W. ToprakU.H. TorrentsD. TortoraG. TostJ. TotokiY. TownendD. TraficanteN. TreilleuxI. TrottaJ-R. TrümperL.H.P. TsaoM. TsunodaT. TubioJ.M.C. TuckerO. TurkingtonR. TurnerD.J. TuttA. UenoM. UenoN.T. UmbrichtC. UmerH.M. UnderwoodT.J. UrbanL. UrushidateT. UshikuT. Uusküla-ReimandL. ValenciaA. Van Den BergD.J. Van LaereS. Van LooP. Van MeirE.G. Van den EyndenG.G. Van der KwastT. VasudevN. VazquezM. VedururuR. VeluvoluU. VembuS. VerbekeL.P.C. VermeulenP. VerrillC. ViariA. VicenteD. VicentiniC. VijayRaghavanK. ViksnaJ. VilainR.E. VillasanteI. Vincent-SalomonA. VisakorpiT. VoetD. VyasP. Vázquez-GarcíaI. WaddellN.M. WaddellN. WadeliusC. WadiL. WagenerR. WalaJ.A. WangJ. WangJ. WangL. WangQ. WangW. WangY. WangZ. WaringP.M. WarnatzH-J. WarrellJ. WarrenA.Y. WaszakS.M. WedgeD.C. WeichenhanD. WeinbergerP. WeinsteinJ.N. WeischenfeldtJ. WeisenbergerD.J. WelchI. WendlM.C. WernerJ. WhalleyJ.P. WheelerD.A. WhitakerH.C. WigleD. WilkersonM.D. WilliamsA. WilmottJ.S. WilsonG.W. WilsonJ.M. WilsonR.K. WinterhoffB. WintersingerJ.A. WiznerowiczM. WolfS. WongB.H. WongT. WongW. WooY. WoodS. WoutersB.G. WrightA.J. WrightD.W. WrightM.H. WuC-L. WuD-Y. WuG. WuJ. WuK. WuY. WuZ. XiL. XiaT. XiangQ. XiaoX. XingR. XiongH. XuQ. XuY. XueH. YachidaS. YakneenS. YamaguchiR. YamaguchiT.N. YamamotoM. YamamotoS. YamaueH. YangF. YangH. YangJ.Y. YangL. YangL. YangS. YangT-P. YangY. YaoX. YaspoM-L. YatesL. YauC. YeC. YeK. YellapantulaV.D. YoonC.J. YoonS-S. YousifF. YuJ. YuK. YuW. YuY. YuanK. YuanY. YuenD. YungC.K. ZaikovaO. ZamoraJ. ZapatkaM. ZenklusenJ.C. ZenzT. ZepsN. ZhangC-Z. ZhangF. ZhangH. ZhangH. ZhangH. ZhangJ. ZhangJ. ZhangJ. ZhangX. ZhangX. ZhangY. ZhangZ. ZhaoZ. ZhengL. ZhengX. ZhouW. ZhouY. ZhuB. ZhuH. ZhuJ. ZhuS. ZouL. ZouX. deFazioA. van AsN. van DeurzenC.H.M. van de VijverM.J. van’t VeerL. von MeringC. The evolutionary history of 2,658 cancers.Nature2020578779312212810.1038/s41586‑019‑1907‑732025013
     [Google Scholar]
  44. BoutinA.T. LiaoW.T. WangM. HwangS.S. KarpinetsT.V. CheungH. ChuG.C. JiangS. HuJ. ChangK. VilarE. SongX. ZhangJ. KopetzS. FutrealA. WangY.A. KwongL.N. DePinhoR.A. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.Genes Dev.201731437038210.1101/gad.293449.11628289141
     [Google Scholar]
  45. QuirkeP. RisioM. LambertR. von KarsaL. ViethM. Quality assurance in pathology in colorectal cancer screening and diagnosis—European recommendations.Virchows Arch.2011458111910.1007/s00428‑010‑0977‑621061133
     [Google Scholar]
  46. SnoverD.C. Update on the serrated pathway to colorectal carcinoma.Hum. Pathol.201142111010.1016/j.humpath.2010.06.00220869746
     [Google Scholar]
  47. TakaiD. JonesP.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22.Proc. Natl. Acad. Sci.20029963740374510.1073/pnas.05241009911891299
     [Google Scholar]
  48. ToyotaM. AhujaN. Ohe-ToyotaM. HermanJ.G. BaylinS.B. IssaJ.P.J. CpG island methylator phenotype in colorectal cancer.Proc. Natl. Acad. Sci.199996158681868610.1073/pnas.96.15.868110411935
     [Google Scholar]
  49. NoffsingerA.E. Serrated polyps and colorectal cancer: new pathway to malignancy.Annu. Rev. Pathol.20094134336410.1146/annurev.pathol.4.110807.09231719400693
     [Google Scholar]
  50. EastJ.E. SaundersB.P. JassJ.R. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management.Gastroenterol. Clin. North Am.20083712546, v10.1016/j.gtc.2007.12.01418313538
     [Google Scholar]
  51. SnoverD.C. Serrated polyps of the large intestine.Semin. Diagn. Pathol.200522430130810.1053/j.semdp.2006.04.00316939058
     [Google Scholar]
  52. SnoverD.C. JassJ.R. Fenoglio-PreiserC. BattsK.P. Serrated polyps of the large intestine: A morphologic and molecular review of an evolving concept.Am. J. Clin. Pathol.2005124338039110.1309/V2EPTPLJRB3FGHJL16191506
     [Google Scholar]
  53. JeongM. GoodellM.A. New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells.Exp. Hematol.201442860961710.1016/j.exphem.2014.04.00824993071
     [Google Scholar]
  54. KaurH. BhallaS. RaghavaG.P.S. Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles.PLoS One2019149e022147610.1371/journal.pone.022147631490960
     [Google Scholar]
  55. HuJ. ZhaoF. HuangB. RanJ. ChenM. LiuH. DengY. ZhaoX. HanX. An eight-CpG-based methylation classifier for preoperative discriminating early and advanced-late stage of colorectal cancer.Front. Genet.20211161416010.3389/fgene.2020.61416033519917
     [Google Scholar]
  56. Nazemalhosseini MojaradE. KuppenP.J. AghdaeiH.A. ZaliM.R. The CpG island methylator phenotype (CIMP) in colorectal cancer.Gastroenterol. Hepatol. Bed Bench20136312012824834258
     [Google Scholar]
  57. JassJ.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.Histopathology200750111313010.1111/j.1365‑2559.2006.02549.x17204026
     [Google Scholar]
  58. De RosaM. RegaD. CostabileV. DuraturoF. NiglioA. IzzoP. PaceU. DelrioP. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.Therap. Adv. Gastroenterol.20169686188610.1177/1756283X1665979027803741
     [Google Scholar]
  59. BaraultL. Charon-BarraC. JoosteV. de la VegaM.F. MartinL. RoignotP. RatP. BouvierA.M. Laurent-PuigP. FaivreJ. ChapusotC. PiardF. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.Cancer Res.200868208541854610.1158/0008‑5472.CAN‑08‑117118922929
     [Google Scholar]
  60. YagiK. AkagiK. HayashiH. NagaeG. TsujiS. IsagawaT. Three epigenotypes of DNA methylation in human colorectal cancer.Clin. Cancer Res.201016213310.1158/1078‑0432.CCR‑09‑200620028768
     [Google Scholar]
  61. ShenL. CatalanoP.J. BensonA.B.III O’DwyerP. HamiltonS.R. IssaJ.P.J. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.Clin. Cancer Res.200713206093609810.1158/1078‑0432.CCR‑07‑101117947473
     [Google Scholar]
  62. GuinneyJ. DienstmannR. WangX. de ReynièsA. SchlickerA. SonesonC. MarisaL. RoepmanP. NyamundandaG. AngelinoP. BotB.M. MorrisJ.S. SimonI.M. GersterS. FesslerE. De Sousa E MeloF. MissiagliaE. RamayH. BarrasD. HomicskoK. MaruD. ManyamG.C. BroomB. BoigeV. Perez-VillamilB. LaderasT. SalazarR. GrayJ.W. HanahanD. TaberneroJ. BernardsR. FriendS.H. Laurent-PuigP. MedemaJ.P. SadanandamA. WesselsL. DelorenziM. KopetzS. VermeulenL. TejparS. The consensus molecular subtypes of colorectal cancer.Nat. Med.201521111350135610.1038/nm.396726457759
     [Google Scholar]
  63. RebersekM. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.Radiol. Oncol.202054327227710.2478/raon‑2020‑003132463385
     [Google Scholar]
  64. ParkS.C. SohnD.K. KimM.J. ChangH.J. HanK.S. HyunJ.H. JooJ. OhJ.H. Phase II clinical trial to evaluate the efficacy of transanal endoscopic total mesorectal excision for rectal cancer.Dis. Colon Rectum201861555456010.1097/DCR.000000000000105829624549
     [Google Scholar]
  65. MillerK.D. NogueiraL. MariottoA.B. RowlandJ.H. YabroffK.R. AlfanoC.M. JemalA. KramerJ.L. SiegelR.L. Cancer treatment and survivorship statistics, 2019.CA Cancer J. Clin.201969536338510.3322/caac.2156531184787
     [Google Scholar]
  66. OguraA. KonishiT. CunninghamC. Garcia-AguilarJ. IversenH. TodaS. LeeI.K. LeeH.X. UeharaK. LeeP. PutterH. van de VeldeC.J.H. BeetsG.L. RuttenH.J.T. KustersM. Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: Results of the multicenter lateral node study of patients with low cT3/4 rectal cancer.J. Clin. Oncol.2019371334310.1200/JCO.18.0003230403572
     [Google Scholar]
  67. JohdiN.A. SukorN.F. Colorectal cancer immunotherapy: Options and strategies.Front. Immunol.202011162410.3389/fimmu.2020.0162433042104
     [Google Scholar]
  68. PardiniB. KumarR. NaccaratiA. NovotnyJ. PrasadR.B. ForstiA. HemminkiK. VodickaP. Lorenzo BermejoJ. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.Br. J. Clin. Pharmacol.201172116216310.1111/j.1365‑2125.2010.03892.x21204909
     [Google Scholar]
  69. CalvoE. CortésJ. RodríguezJ. Fernández-HidalgoÓ. RebolloJ. Martín-AlgarraS. García-FoncillasJ. Martínez-MongeR. de IralaJ. BrugarolasA. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: A phase II study.Clin. Colorectal Cancer20022210411010.3816/CCC.2002.n.01612453325
     [Google Scholar]
  70. YuanY. XiaoW.W. XieW.H. CaiP.Q. WangQ.X. ChangH. ChenB.Q. ZhouW.H. ZengZ.F. WuX.J. LiuQ. LiL.R. ZhangR. GaoY.H. Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: A potential improvement to overall survival and decrease to multivisceral resection.BMC Cancer202121117910.1186/s12885‑021‑07894‑633607964
     [Google Scholar]
  71. ZhengS. TaoW. Identification of novel transcriptome signature as a potential prognostic biomarker for anti-angiogenic therapy in glioblastoma multiforme.Cancers20201210.3390/cancers1209236833804433
     [Google Scholar]
  72. HaoZ. ParasramkaS. ChenQ. JacobA. HuangB. MullettT. BensonA.B. Neoadjuvant versus adjuvant chemotherapy for resectable metastatic colon cancer in non-academic and academic programs.Oncologist2022281485810.1093/oncolo/oyac20936200844
     [Google Scholar]
  73. NormannoN. TejparS. MorgilloF. De LucaA. Van CutsemE. CiardielloF. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.Nat. Rev. Clin. Oncol.20096951952710.1038/nrclinonc.2009.11119636327
     [Google Scholar]
  74. ShenW.D. ChenH.L. LiuP.F. EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: A meta-analysis.Chin. J. Cancer Res.2014261597110.3978/j.issn.1000‑9604.2014.01.1024653627
     [Google Scholar]
  75. CohenM.H. GootenbergJ. KeeganP. PazdurR. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.Oncologist200712335636110.1634/theoncologist.12‑3‑35617405901
     [Google Scholar]
  76. TangP.A. CohenS.J. KollmannsbergerC. BjarnasonG. VirikK. MacKenzieM.J. LourencoL. WangL. ChenA. MooreM.J. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.Clin. Cancer Res.201218216023603110.1158/1078‑0432.CCR‑11‑325222977191
     [Google Scholar]
  77. PiawahS. VenookA.P. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.Cancer2019125234139414710.1002/cncr.3216331433498
     [Google Scholar]
  78. WojtukiewiczM.Z. RekM.M. KarpowiczK. GórskaM. PolityńskaB. WojtukiewiczA.M. MoniuszkoM. RadziwonP. TuckerS.C. HonnK.V. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners.Cancer Metastasis Rev.202140394998210.1007/s10555‑021‑09976‑034236546
     [Google Scholar]
  79. PatsoukisN. BrownJ. PetkovaV. LiuF. LiL. BoussiotisV.A. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.Sci. Signal.20125230ra4610.1126/scisignal.200279622740686
     [Google Scholar]
  80. García-ArandaM. RedondoM. Immunotherapy: A challenge of breast cancer treatment.Cancers20191112182210.3390/cancers1112182231756919
     [Google Scholar]
  81. FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer2017Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-msi-h-or-dmmr-colorectal-cancer#:~:text=On%20July%2031%2C%202017%2C%20the,colorectal%20cancer%20that%20has%20progressed
  82. MarcusL. LemeryS.J. KeeganP. PazdurR. FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors.Clin. Cancer Res.201925133753375810.1158/1078‑0432.CCR‑18‑407030787022
     [Google Scholar]
  83. Administration, F.a.D.FDA approves first-line immunotherapy for patients with MSI-H/dMMR metastatic.2020Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer#:~:text=On%20June%2029%2C%202020%2C%20the,deficient%20(dMMR)%20colorectal%20cancer.
    [Google Scholar]
  84. AndréT. ShiuK.K. KimT.W. JensenB.V. JensenL.H. PuntC. SmithD. Garcia-CarboneroR. BenavidesM. GibbsP. de la FouchardiereC. RiveraF. ElezE. BendellJ. LeD.T. YoshinoT. Van CutsemE. YangP. FarooquiM.Z.H. MarinelloP. DiazL.A.Jr Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.N. Engl. J. Med.2020383232207221810.1056/NEJMoa201769933264544
     [Google Scholar]
  85. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication2017Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication
  86. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer2020Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer
  87. LeD.T. UramJ.N. WangH. BartlettB.R. KemberlingH. EyringA.D. SkoraA.D. LuberB.S. AzadN.S. LaheruD. BiedrzyckiB. DonehowerR.C. ZaheerA. FisherG.A. CrocenziT.S. LeeJ.J. DuffyS.M. GoldbergR.M. de la ChapelleA. KoshijiM. BhaijeeF. HuebnerT. HrubanR.H. WoodL.D. CukaN. PardollD.M. PapadopoulosN. KinzlerK.W. ZhouS. CornishT.C. TaubeJ.M. AndersR.A. EshlemanJ.R. VogelsteinB. DiazL.A.Jr PD-1 blockade in tumors with mismatch-repair deficiency.N. Engl. J. Med.2015372262509252010.1056/NEJMoa150059626028255
     [Google Scholar]
  88. de WiedD. Peptide hormones and neuropeptides: birds of a feather.Trends Neurosci.200023311310.1016/S0166‑2236(99)01511‑810675911
     [Google Scholar]
  89. BurbachJ.P. Neuropeptides from concept to online database.J. Pharmacol20106262748
     [Google Scholar]
  90. HökfeltT. BartfaiT. BloomF. Neuropeptides: opportunities for drug discovery.Lancet Neurol.20032846347210.1016/S1474‑4422(03)00482‑412878434
     [Google Scholar]
  91. RomanovaE.V. SweedlerJ.V. Peptidomics for the discovery and characterization of neuropeptides and hormones.Trends Pharmacol. Sci.201536957958610.1016/j.tips.2015.05.00926143240
     [Google Scholar]
  92. SteinhoffM.S. von MentzerB. GeppettiP. PothoulakisC. BunnettN.W. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.Physiol. Rev.201494126530110.1152/physrev.00031.201324382888
     [Google Scholar]
  93. MartínezA.N. PhilippM.T. Substance P and neuoquinin-1 receptor antagonists in neuroinflammation associated with infectious and neurodegenerative diseases of the central nervous system.J. Neurol. Neuromedicine20161293610.29245/2572.942X/2016/2.102027430034
     [Google Scholar]
  94. WergeT. The tachykinin tale: Molecular recognition in a historical perspective.J. Mol. Recognit.200720314515310.1002/jmr.82217444559
     [Google Scholar]
  95. BremerA.A. LeemanS.E. BoydN.D. The common C-terminal sequences of substance P and neurokinin A contact the same region of the NK-1 receptor.FEBS Lett.20004861434810.1016/S0014‑5793(00)02228‑611108840
     [Google Scholar]
  96. GoldsmithL.E. KwatraM.M. Tachykinin/substance P/neurokinin-1 receptors.Encyclopedia of Biological Chemistry.Waltham, MAAcademic Press2013360365
     [Google Scholar]
  97. LorestaniS. GhahremanlooA. JangjooA. AbediM. HashemyS.I. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer.Mol. Biol. Rep.20204753469347410.1007/s11033‑020‑05432‑432277443
     [Google Scholar]
  98. García-ArandaM. TéllezT. McKennaL. RedondoM. Neurokinin-1 receptor-1 (NK-1R) antagonists as a new strategy to overcome cancer resistance.Cancers2022149225510.3390/cancers1409225535565383
     [Google Scholar]
  99. PatacchiniR. MaggiC.A. Peripheral tachykinin receptors as targets for new drugs.Eur. J. Pharmacol.20014291-3132110.1016/S0014‑2999(01)01301‑211698023
     [Google Scholar]
  100. NCBI TAC1 Precursor de taquiquinina 1 [Homo Sapiens (humano)]Available from: https://www.ncbi.nlm.nih.gov/gene/6863 (Accessed August 16, 2022).
  101. PageN.M. New challenges in the study of the mammalian tachykinins.Peptides20052681356136810.1016/j.peptides.2005.03.03016042976
     [Google Scholar]
  102. El gen TAC3 de la base de datos de genes humanosAvailable from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TAC3 (Accessed August 16, 2022).
  103. NCBI TAC3 Precursor de taquiquinina 3 [Homo Sapiens (humano)]Available from: https://www.ncbi.nlm.nih.gov/gene/6866 (Accessed August 16, 2022).
  104. UNIProt UniProtKB–Q86UU9 (TKN4_HUMAN)Available from: https://www.uniprot.org/uniprot/Q86UU9 (Accessed August 16, 2022).
  105. NCBI TAC4 Precursor de taquiquinina 4 [Homo Sapiens (humano)]Available from: https://www.ncbi.nlm.nih.gov/gene/255061 (Accessed August 16, 2022).
  106. HoW.Z. LaiJ.P. ZhuX.H. UvaydovaM. DouglasS.D. Human monocytes and macrophages express substance P and neurokinin-1 receptor.J. Immunol.1997159115654566010.4049/jimmunol.159.11.56549548509
     [Google Scholar]
  107. McGillisJ.P. MitsuhashiM. PayanD.G. Immunological properties of substance P.Psychoneuroimmunology. AderR. Academic Press199120922310.1016/B978‑0‑12‑043780‑1.50011‑7
     [Google Scholar]
  108. MooreT.C. LamiJ.L. SpruckC.H. Substance P increases lymphocyte traffic and lymph flow through peripheral lymph nodes of sheep.Immunology19896711091142472354
     [Google Scholar]
  109. StaniszA.M. BefusD. BienenstockJ. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer’s patches, mesenteric lymph nodes, and spleen.J. Immunol.1986136115215610.4049/jimmunol.136.1.1522415614
     [Google Scholar]
  110. LotzM. VaughanJ.H. CarsonD.A. Effect of neuropeptides on production of inflammatory cytokines by human monocytes.Science198824148701218122110.1126/science.24579502457950
     [Google Scholar]
  111. HartungH.P. ToykaK.V. Activation of macrophages by substance P: Induction of oxidative burst and thromboxane release.Eur. J. Pharmacol.1983893-430130510.1016/0014‑2999(83)90511‑36191998
     [Google Scholar]
  112. MuñozM. CoveñasR. Neurokinin receptor antagonism: A patent review (2014-present).Expert Opin. Ther. Pat.202030752753910.1080/13543776.2020.176959932401556
     [Google Scholar]
  113. MantovaniA. AllavenaP. SicaA. BalkwillF. Cancer-related inflammation.Nature2008454720343644410.1038/nature0720518650914
     [Google Scholar]
  114. RossoM. MuñozM. BergerM. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.ScientificWorldJournal2012201212110.1100/2012/38143422545017
     [Google Scholar]
  115. FengF. YangJ. TongL. YuanS. TianY. HongL. WangW. ZhangH. Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells.Cell Biol. Int.201135662362910.1042/CBI2010022921091434
     [Google Scholar]
  116. Bar-ShavitZ. GoldmanR. StabinskyY. GottliebP. FridkinM. TeichbergV.I. BlumbergS. Enhancement of phagocytosis - A newly found activity of Substance P residing in its N-terminal tetrapeptide sequence.Biochem. Biophys. Res. Commun.19809441445145110.1016/0006‑291X(80)90581‑16156684
     [Google Scholar]
  117. KageR. LeemanS.E. BoydN.D. Biochemical characterization of two different forms of the substance P receptor in rat submaxillary gland.J. Neurochem.199360134735110.1111/j.1471‑4159.1993.tb05857.x8380195
     [Google Scholar]
  118. UniProt UniProtKB-P25103Available from: https://www.uniprot.org/uniprot/P25103 (Accessed Jul 5, 2023)
  119. GerardN.P. GarrawayL.A. EddyR.L. Human substance P receptor (NK-1): Gene organization, chromosomal localization, and functional expression of cDNA clones.Biochemistry199130106401064610.1021/bi00108a0061657150
     [Google Scholar]
  120. O’ConnorT.M. O’ConnellJ. O’BrienD.I. GoodeT. BredinC.P. ShanahanF. The role of substance P in inflammatory disease.J. Cell. Physiol.2004201216718010.1002/jcp.2006115334652
     [Google Scholar]
  121. LaiJ.P. LaiS. TulucF. TanskyM.F. KilpatrickL.E. LeemanS.E. DouglasS.D. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor.Proc. Natl. Acad. Sci.200810534126051261010.1073/pnas.080663210518713853
     [Google Scholar]
  122. GhahremanlooA. JavidH. AfshariA.R. HashemyS.I. Investigation of the role of neurokinin-1 receptor inhibition with aprepitant in apoptotic cell death via PI3K/Akt/NF- κ B signal transduction pathways in colon cancer cells.BioMed Res. Int.2021202111010.1155/2021/138387834395609
     [Google Scholar]
  123. SpitsinS. PappaV. DouglasS.D. Truncation of neurokinin-1 receptor-Negative regulation of substance P signaling.J. Leukoc. Biol.201810361043105110.1002/JLB.3MIR0817‑348R29345372
     [Google Scholar]
  124. RamkissoonS.H. PatelP.S. TaborgaM. RameshwarP. Nuclear factor kappaB is critical for truncated neurokinin-1 receptor expression in breast cancer: Implication for quiescence of breast cancer cells within the bone marrow stroma.Cancer Res.2007671653165910.1158/0008‑5472.CAN‑06‑381317308106
     [Google Scholar]
  125. PatelH.J. RamkissoonS.H. PatelP.S. RameshwarP. Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides.Proc. Natl. Acad. Sci.200510248174361744110.1073/pnas.050635110216291810
     [Google Scholar]
  126. BigioniM. BenzoA. IrrissutoC. MaggiC.A. GosoC. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231.Anticancer Drugs200516101083108910.1097/00001813‑200511000‑0000716222150
     [Google Scholar]
  127. GaoX. WangZ. Difference in expression of two neurokinin-1 receptors in adenoma and carcinoma from patients that underwent radical surgery for colorectal carcinoma.Oncol. Lett.20171433729373310.3892/ol.2017.658828927139
     [Google Scholar]
  128. IsornaI. EstebanF. SolanellasJ. CoveñasR. MuñozM. The substance P and neurokinin-1 receptor system in human thyroid cancer: An immunohistochemical study.Eur. J. Histochem.2020642311710.4081/ejh.2020.311732363847
     [Google Scholar]
  129. HennigI.M. LaissueJ.A. HorisbergerU. ReubiJ.C. Substance-P receptors in human primary neoplasms: Tumoral and vascular localization.Int. J. Cancer199561678679210.1002/ijc.29106106087790112
     [Google Scholar]
  130. MuñozM. CoveñasR. Involvement of substance P and the NK-1 receptor in pancreatic cancer.World J. Gastroenterol.20142092321233410.3748/wjg.v20.i9.232124605029
     [Google Scholar]
  131. JavidH. AsadiJ. Zahedi AvvalF. AfshariA.R. HashemyS.I. The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways.Mol. Biol. Rep.20204732253226310.1007/s11033‑020‑05330‑932072401
     [Google Scholar]
  132. DouglasS.D. LeemanS.E. Neurokinin-1 receptor: Functional significance in the immune system in reference to selected infections and inflammation.Ann. N. Y. Acad. Sci.201112171839510.1111/j.1749‑6632.2010.05826.x21091716
     [Google Scholar]
  133. LiuR. ChenY. LiuG. LiC. SongY. CaoZ. LiW. HuJ. LuC. LiuY. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.Cell Death Dis.202011979710.1038/s41419‑020‑02998‑632973135
     [Google Scholar]
  134. SalaroglioI.C. MungoE. GazzanoE. KopeckaJ. RigantiC. ERK is a pivotal player of chemo-immune-resistance in cancer.Int. J. Mol. Sci.20192010250510.3390/ijms2010250531117237
     [Google Scholar]
  135. DeFeaK.A. VaughnZ.D. O’BryanE.M. NishijimaD. DéryO. BunnettN.W. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex.Proc. Natl. Acad. Sci.20009720110861109110.1073/pnas.19027669710995467
     [Google Scholar]
  136. DengX.T. TangS.M. WuP.Y. LiQ.P. GeX.X. XuB.M. WangH.S. MiaoL. SP/NK-1R promotes gallbladder cancer cell proliferation and migration.J. Cell. Mol. Med.201923127961797310.1111/jcmm.1423030903649
     [Google Scholar]
  137. Bentires-AljM. BarbuV. FilletM. ChariotA. RelicB. JacobsN. GielenJ. MervilleM.P. BoursV. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells.Oncogene2003221909710.1038/sj.onc.120605612527911
     [Google Scholar]
  138. Di MaioM. BriaE. BannaG.L. PuglisiF. GarassinoM.C. LorussoD. PerroneF. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors.Anticancer Drugs20132429911110.1097/CAD.0b013e328359d7ba23165435
     [Google Scholar]
  139. CassidyJ. ClarkeS. Díaz-RubioE. ScheithauerW. FigerA. WongR. KoskiS. LichinitserM. YangT.S. RiveraF. CoutureF. SirzénF. SaltzL. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.J. Clin. Oncol.200826122006201210.1200/JCO.2007.14.989818421053
     [Google Scholar]
  140. ShimokawaM. HayashiT. NishimuraJ. SatohT. FukunagaM. MatsuiR. TsujiY. MizukiF. KogawaT. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.BMC Cancer2021211111110.1186/s12885‑021‑08860‑y34656107
     [Google Scholar]
  141. VidallC. Fernández-OrtegaP. CortinovisD. JahnP. AmlaniB. ScottéF. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: A cross-sectional multinational survey.Support. Care Cancer201523113297330510.1007/s00520‑015‑2750‑525953380
     [Google Scholar]
  142. HeskethP.J. Chemotherapy-induced nausea and vomiting.N. Engl. J. Med.2008358232482249410.1056/NEJMra070654718525044
     [Google Scholar]
  143. NavariR.M. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.Expert Opin. Drug Saf.201615334335610.1517/14740338.2016.113589926699406
     [Google Scholar]
  144. HeskethP.J. KrisM.G. BaschE. BohlkeK. BarbourS.Y. Clark-SnowR.A. DansoM.A. DennisK. DupuisL.L. DusetzinaS.B. EngC. FeyerP.C. JordanK. NoonanK. SparacioD. SomerfieldM.R. LymanG.H. Antiemetics: Update to the american society of clinical oncology clinical practice guideline.J. Clin. Oncol.201735283240326110.1200/JCO.2017.74.478928759346
     [Google Scholar]
  145. NavariR.M. AaproM. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.N. Engl. J. Med.2016374141356136710.1056/NEJMra151544227050207
     [Google Scholar]
  146. SchwartzbergL.S. ModianoM.R. RapoportB.L. ChasenM.R. GridelliC. UrbanL. PomaA. AroraS. NavariR.M. SchnadigI.D. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: A randomised, active-controlled, double-blind, phase 3 trial.Lancet Oncol.20151691071107810.1016/S1470‑2045(15)00034‑026272768
     [Google Scholar]
  147. AaproM. CINV: Patients still worrying after all these years.Cancer Support Care2018265910.1007/s00520‑018‑4131‑329556808
     [Google Scholar]
  148. European Medicines Agency EMENDINN-Aprepitant: Scientific Discussion.2004Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/emend-epar-scientific-discussion_en.pdf (Accessed August 17, 2022)
  149. MuñozM. CoveñasR. The neurokinin-1 receptor antagonist aprepitant: A smart bullet against cancer?Cancers2020129268210.3390/cancers1209268232962202
     [Google Scholar]
  150. RobinsonP. KasembeliM. BharadwajU. EngineerN. EckolsK.T. TweardyD.J. SubstanceP. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance.BioMed Res. Int.201620161910.1155/2016/195927026981525
     [Google Scholar]
  151. MuñozM. González-OrtegaA. Salinas-MartínM.V. CarranzaA. Garcia-RecioS. AlmendroV. CoveñasR. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.Int. J. Oncol.20144541658167210.3892/ijo.2014.256525175857
     [Google Scholar]
  152. NizamE. ErinN. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.Biomed. Pharmacother.201810826327010.1016/j.biopha.2018.09.01330223097
     [Google Scholar]
  153. ZhangX.W. LiL. HuW.Q. HuM.N. TaoY. HuH. MiaoX.K. YangW.L. ZhuQ. MouL.Y. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR.Cell Death Dis.20221314110.1038/s41419‑021‑04485‑y35013118
     [Google Scholar]
  154. MatalińskaJ. ŚwićA. LipińskiP. MisickaA. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.Folia Neuropathol.202058323724410.5114/fn.2020.10006633099293
     [Google Scholar]
  155. MuñozM. CoveñasR. Involvement of substance P and the NK-1 receptor in cancer progression.Peptides2013481910.1016/j.peptides.2013.07.02423933301
     [Google Scholar]
  156. BeirithI. RenzB.W. MudusettiS. RingN.S. KolorzJ. KochD. BazhinA.V. BergerM. WangJ. AngeleM.K. D’HaeseJ.G. GubaM.O. NiessH. AndrassyJ. WernerJ. IlmerM. Identification of the neurokinin-1 receptor as targetable stratification factor for drug repurposing in pancreatic cancer.Cancers20211311270310.3390/cancers1311270334070805
     [Google Scholar]
  157. EbrahimiS. MirzaviF. Aghaee-BakhtiariS.H. HashemyS.I. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.Biochim. Biophys. Acta Mol. Cell Res.20221869511922110.1016/j.bbamcr.2022.11922135134443
     [Google Scholar]
  158. TakeiS. IshibeA. WatanabeJ. WatanabeK. SuwaY. SuzukiS. NakagawaK. SuwaH. OtaM. IchikawaY. KunisakiC. YamanakaT. EndoI. Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: A prospective cohort study (YCOG1301).Int. J. Colorectal Dis.202035122323232910.1007/s00384‑020‑03731‑732860080
     [Google Scholar]
  159. GarnierA. VykoukalJ. HubertusJ. AltE. Von SchweinitzD. KapplerR. BergerM. IlmerM. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.Int. J. Oncol.201547115116010.3892/ijo.2015.301625998227
     [Google Scholar]
  160. GhahremanlooA. JavidH. AfshariA.R. HashemyS.I. Investigation of the role of neurokinin-1 receptor inhibition using aprepitant in the apoptotic cell death through PI3K/Akt/NF-κB signal transduction pathways in colon cancer cells.BioMed Res. Int.2021202111010.1155/2021/138387834395609
     [Google Scholar]
  161. KoonH.W. ZhaoD. NaX. MoyerM.P. PothoulakisC. Metalloproteinases and transforming growth factor-α mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes.J. Biol. Chem.200427944455194552710.1074/jbc.M40852320015319441
     [Google Scholar]
  162. StucchiA.F. ShoferS. LeemanS. MaterneO. BeerE. McClungJ. ShebaniK. MooreF. O’BrienM. BeckerJ.M. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats.Am. J. Physiol. Gastrointest. Liver Physiol.20002796G1298G130610.1152/ajpgi.2000.279.6.G129811093954
     [Google Scholar]
  163. CastagliuoloI. MorteauO. KeatesA.C. ValenickL. WangC.C. ZacksJ. LuB. GerardN.P. PothoulakisC. Protective effects of neurokinin-1 receptor during colitis in mice: Role of the epidermal growth factor receptor.Br. J. Pharmacol.2002136227127910.1038/sj.bjp.070469712010776
     [Google Scholar]
  164. RossoM. Robles-FríasM.J. CoveñasR. Salinas-MartínM.V. MuñozM. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.Tumour Biol.200829424525410.1159/00015294218781096
     [Google Scholar]
  165. PagánB. IsidroA.A. CoppolaD. ChenZ. RenY. WuJ. AppleyardC.B. Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer.Anticancer Res.20103093345335320944107
     [Google Scholar]
  166. LegiA. RodriguezE. EckolsT.K. MistryC. RobinsonP. SubstanceP. Substance P antagonism prevents chemotherapy-induced cardiotoxicity.Cancers2021137173210.3390/cancers1307173233917491
     [Google Scholar]
  167. RapoportB. AaproM. ChasenM. JordanK. NavariR. SchnadigI. SchwartzbergL. Recent developments in the clinical pharmacology of rolapitant: Subanalyses in specific populations.Drug Des. Devel. Ther.2017112621262910.2147/DDDT.S13394328919712
     [Google Scholar]
  168. LeeM. McCloskeyM. StaplesS. Prolonged use of aprepitant in metastatic breast cancer and a reduction in CA153 tumour marker levels.Int. J. Cancer Clin. Res.2016307110.23937/2378‑3419/3/6/1071
     [Google Scholar]
  169. MuñozM. CrespoJ.C. CrespoJ.P. CoveñasR. Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report.Mol. Clin. Oncol.2019111505410.3892/mco.2019.185731289677
     [Google Scholar]
  170. FDAApproves first cancer treatment for any solid tumor with a specific genetic feature.2017Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature (Accessed on: February 5, 2023)
  171. ZhaoL. LeeV.H.F. NgM.K. YanH. BijlsmaM.F. Molecular subtyping of cancer: Current status and moving toward clinical applications.Brief. Bioinform.201920257258410.1093/bib/bby02629659698
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673261625230924114406
Loading
The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer
Curr. Med. Chem. 31, 6487 (2024); https://doi.org/10.2174/0109298673261625230924114406
/content/journals/cmc/10.2174/0109298673261625230924114406
/content/journals/cmc/10.2174/0109298673261625230924114406
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): aprepitant; colorectal cancer; pharmacological repositioning; Substance P, neurokinin-1 receptor; targeted treatment

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test